Teva Pharmaceutical Industries (NYSE:TEVA) Stock Rating Lowered by StockNews.com

Teva Pharmaceutical Industries (NYSE:TEVA) was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

A number of other equities analysts also recently commented on TEVA. Piper Sandler upped their target price on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the stock an “overweight” rating in a research note on Friday, January 17th. Barclays dropped their target price on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating on the stock in a research report on Thursday, January 30th. UBS Group reduced their price target on Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Finally, Bank of America cut their price target on shares of Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating on the stock in a report on Thursday, March 6th. Two equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, Teva Pharmaceutical Industries has an average rating of “Moderate Buy” and an average target price of $23.43.

Teva Pharmaceutical Industries Price Performance

Teva Pharmaceutical Industries stock opened at $15.68 on Thursday. Teva Pharmaceutical Industries has a 12-month low of $12.51 and a 12-month high of $22.80. The company has a current ratio of 0.98, a quick ratio of 0.75 and a debt-to-equity ratio of 2.97. The firm has a 50-day moving average price of $17.47 and a 200-day moving average price of $18.16. The firm has a market capitalization of $17.77 billion, a PE ratio of -10.81, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its quarterly earnings data on Wednesday, January 29th. The company reported $0.70 EPS for the quarter, beating the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a positive return on equity of 42.46% and a negative net margin of 9.91%. As a group, equities research analysts forecast that Teva Pharmaceutical Industries will post 2.5 EPS for the current year.

Institutional Investors Weigh In On Teva Pharmaceutical Industries

A number of hedge funds have recently modified their holdings of the business. FMR LLC increased its holdings in shares of Teva Pharmaceutical Industries by 30.7% in the fourth quarter. FMR LLC now owns 81,983,231 shares of the company’s stock valued at $1,806,910,000 after purchasing an additional 19,242,468 shares during the last quarter. Clal Insurance Enterprises Holdings Ltd raised its holdings in shares of Teva Pharmaceutical Industries by 12.8% during the 4th quarter. Clal Insurance Enterprises Holdings Ltd now owns 38,962,773 shares of the company’s stock worth $859,935,000 after acquiring an additional 4,418,961 shares during the period. Ion Asset Management Ltd. boosted its position in shares of Teva Pharmaceutical Industries by 1.1% during the 4th quarter. Ion Asset Management Ltd. now owns 36,650,000 shares of the company’s stock valued at $807,766,000 after acquiring an additional 409,778 shares during the last quarter. Lingotto Investment Management LLP grew its holdings in shares of Teva Pharmaceutical Industries by 2.6% in the fourth quarter. Lingotto Investment Management LLP now owns 27,192,388 shares of the company’s stock valued at $599,320,000 after purchasing an additional 688,862 shares during the period. Finally, Migdal Insurance & Financial Holdings Ltd. raised its stake in Teva Pharmaceutical Industries by 2.2% during the fourth quarter. Migdal Insurance & Financial Holdings Ltd. now owns 26,035,422 shares of the company’s stock worth $573,822,000 after purchasing an additional 569,412 shares during the period. 54.05% of the stock is currently owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.